Healthcare Industry News: osteoporosis
News Release - March 20, 2008
Zelos Therapeutics Appoints David S. Krause, MD, FACP, as Chief Medical OfficerWEST CONSHOHOCKEN, Pa.--(HSMN NewsFeed)--Zelos Therapeutics, Inc. today announced the appointment of David S. Krause, MD, FACP, as the Company’s Senior Vice President of R&D and Chief Medical Officer. Dr. Krause has served as a clinical and regulatory advisor to Zelos since 2006 and brings over 18 years of biopharmaceutical development experience to the Company.
“David’s highly successful career in biopharmaceutical drug development, in particular his significant experience with late-stage product advancement, makes him an ideal addition to our management team,” stated Brian MacDonald, MB, ChB, PhD, Chief Executive Officer of Zelos. “His broad experience and capabilities will be essential as Zelos moves its lead program into Phase 3 trials in osteoporosis this year and also initiates clinical programs in fracture repair and hematology indications over the next year.”
“I am delighted to be joining a team which shares my passion for improving treatment options for patients with bone disorders and related indications,” said Dr. Krause. “The Company’s specialized expertise in bone and bone marrow diseases, combined with the extremely robust outcome of last year’s Phase 2 study in osteoporosis, creates a great opportunity to address significant unmet medical needs in a number of different bone diseases. I look forward to extending my role with Zelos and contributing to the success of the Company as we advance our clinical development programs.”
Prior to joining Zelos, Dr. Krause was a Principal with Delta Pharmaceutical Consulting LLC, a private consulting firm to the pharmaceutical industry. Dr. Krause also served as Chief Medical Officer of Vicuron (which was subsequently acquired by Pfizer) and held various senior drug development and medical affairs leadership positions in multiple relevant clinical groups, including Biologicals, Inflammation and Tissue Repair and Pulmonary and Diabetes, at SmithKline Beecham and GlaxoSmithKline. During his tenure at these companies, Dr. Krause led the successful development and FDA approval of a number of important products in these therapeutic areas.
Dr. Krause has also served as a consultant to the Department of Defense on infectious disease and vaccine-related issues. He received his medical degree from Temple University School of Medicine and trained in internal medicine at the Medical College of Pennsylvania and Temple University Hospital.
About Zelos Therapeutics, Inc.
Zelos Therapeutics specializes in the development of innovative treatments for bone disorders and related indications in large, underserved markets. Led by an experienced team of biopharmaceutical executives and funded by leading health care investors, Zelos is advancing a portfolio of product opportunities into late-stage clinical trials. www.zelostherapeutics.com
Source: Zelos Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.